PYXS

$0.00

(

+0.00%

)
Quote details

stock

Pyxis Oncology Inc

NASDAQ | PYXS

3.66

USD

+$0.00

(

+0.00%

)

At Close (As of Oct 15, 2025)

$226.99M

Market Cap

-

P/E Ratio

-1.59

EPS

$5.39

52 Week High

$0.83

52 Week Low

HEALTHCARE

Sector

PYXS Chart

Recent Chart
Price Action

PYXS Technicals

Tags:

PYXS Earnings

Yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit $16M
Total Revenue $16M
Cost Of Revenue $475K
Costof Goods And Services Sold $475K
Operating Income -$89M
Selling General And Administrative $25M
Research And Development $59M
Operating Expenses $105M
Investment Income Net -
Net Interest Income $7M
Interest Income $7M
Interest Expense -
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $3M
Income Before Tax -$79M
Income Tax Expense -$2.2M
Interest And Debt Expense -
Net Income From Continuing Operations -$77M
Comprehensive Income Net Of Tax -
Ebit -$68M
Ebitda -$66M
Net Income -$77M

Revenue & Profitability

Earnings Performance

PYXS Financials

yearly Balance Sheet (As of Dec 31, 2024)

Field Value (USD)
Total Assets $157M
Total Current Assets $132M
Cash And Cash Equivalents At Carrying Value $19M
Cash And Short Term Investments $19M
Inventory -
Current Net Receivables -
Total Non Current Assets $25M
Property Plant Equipment -
Accumulated Depreciation Amortization Ppe -
Intangible Assets $2.6M
Intangible Assets Excluding Goodwill $2.6M
Goodwill -
Investments -
Long Term Investments -
Short Term Investments $107M
Other Current Assets $5.5M
Other Non Current Assets -
Total Liabilities $36M
Total Current Liabilities $18M
Current Accounts Payable $4.9M
Deferred Revenue -
Current Debt -
Short Term Debt $2.9M
Total Non Current Liabilities $19M
Capital Lease Obligations $20M
Long Term Debt -
Current Long Term Debt -
Long Term Debt Noncurrent -
Short Long Term Debt Total $20M
Other Current Liabilities $9.9M
Other Non Current Liabilities -
Total Shareholder Equity $121M
Treasury Stock -
Retained Earnings -$364M
Common Stock $60K
Common Stock Shares Outstanding $58M

yearly Cash Flow (As of Dec 31, 2024)

Field Value (USD)
Operating Cashflow -$58M
Payments For Operating Activities -
Proceeds From Operating Activities -
Change In Operating Liabilities -
Change In Operating Assets -
Depreciation Depletion And Amortization $3M
Capital Expenditures $237K
Change In Receivables -
Change In Inventory -
Profit Loss -
Cashflow From Investment $8.2M
Cashflow From Financing $59M
Proceeds From Repayments Of Short Term Debt -
Payments For Repurchase Of Common Stock -
Payments For Repurchase Of Equity -
Payments For Repurchase Of Preferred Stock -
Dividend Payout -
Dividend Payout Common Stock -
Dividend Payout Preferred Stock -
Proceeds From Issuance Of Common Stock -
Proceeds From Issuance Of Long Term Debt And Capital Securities Net -
Proceeds From Issuance Of Preferred Stock -
Proceeds From Repurchase Of Equity -
Proceeds From Sale Of Treasury Stock -
Change In Cash And Cash Equivalents -
Change In Exchange Rate -
Net Income -$77M

yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit $16M
Total Revenue $16M
Cost Of Revenue $475K
Costof Goods And Services Sold $475K
Operating Income -$89M
Selling General And Administrative $25M
Research And Development $59M
Operating Expenses $105M
Investment Income Net -
Net Interest Income $7M
Interest Income $7M
Interest Expense -
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $3M
Income Before Tax -$79M
Income Tax Expense -$2.2M
Interest And Debt Expense -
Net Income From Continuing Operations -$77M
Comprehensive Income Net Of Tax -
Ebit -$68M
Ebitda -$66M
Net Income -$77M

PYXS News

PYXS Profile

Pyxis Oncology Inc Profile

Sector: HEALTHCARE

Industry: BIOTECHNOLOGY

Pyxis Oncology, Inc. is a preclinical biotechnology firm based in Cambridge, Massachusetts, focused on advancing innovative therapies for cancer treatment through the development of antibody-drug conjugates (ADCs) and monoclonal antibodies (mAbs). With a commitment to harnessing the power of targeted therapies, Pyxis aims to enhance the efficacy and safety profiles of oncology treatments, addressing unmet medical needs in the oncology landscape. The company's cutting-edge research and strategic partnerships position it for potential breakthroughs in cancer therapy.

VHAI
-20.00%
$0.00
VIVK
-1.72%
$0.28
YYAI
-10.71%
$0.12
BURU
+1.07%
$0.34
EPWK
+26.46%
$0.09
IVF
+85.67%
$1.40
BITF
-18.39%
$5.28
RXRX
-7.21%
$6.29
CGBS
-39.47%
$0.03
COOT
+173.57%
$2.64
NVDA
+1.10%
$181.81
PLUG
-8.70%
$3.51
ADAP
+6.57%
$0.19
BYND
-22.39%
$0.52
YDKG
-54.14%
$0.08
NVTS
+3.10%
$15.63
RGTI
-14.85%
$47.97
DNN
-2.83%
$3.08
LAES
-2.09%
$7.49
NIO
-1.09%
$6.74
MIRA
+36.36%
$1.80
F
-0.12%
$11.74
SCNX
-17.63%
$0.58
BBD
+1.71%
$3.25
WHWK
+24.28%
$2.61
KVUE
-13.34%
$14.09
ACHR
-8.90%
$11.87
INTC
-0.83%
$36.84
TLRY
-8.33%
$1.54
HPE
-10.06%
$22.52
TSLA
-1.47%
$428.75
ONDS
-13.77%
$8.19
IONZ
+18.46%
$3.41
DFLI
-32.48%
$1.33
AXDX
-61.36%
$0.03
ETHD
+6.47%
$3.78
RIG
-2.56%
$3.22
CAN
-14.28%
$1.68
AAL
-4.88%
$11.89
AMD
-1.33%
$235.40
SOFI
-6.13%
$26.31
GDXD
-7.91%
$0.61
MARA
-11.62%
$20.18
BTBT
-9.11%
$3.69
GNPX
-43.39%
$0.47
QBTS
-9.62%
$40.47
BTG
+3.96%
$5.89
FEMY
+33.89%
$0.73
VSEE
-13.85%
$0.51
QS
-13.41%
$15.45
RR
-7.95%
$5.67
GPUS
-6.14%
$0.36
LGCB
+19.39%
$1.97
ABAT
-21.00%
$8.94
NAK
-4.34%
$2.64
SNAP
-1.83%
$7.76
CIFR
-10.98%
$18.72
WOK
+1.55%
$0.05
CRML
-14.52%
$19.42
QSI
-3.23%
$2.54
RF
-5.98%
$23.26
RGTZ
+30.51%
$11.35
PFE
-0.65%
$24.23
MASK
+17.35%
$0.57
UUUU
-12.80%
$21.79
QUBT
-12.12%
$18.65
KEY
-5.35%
$16.78
HBAN
-5.00%
$15.39
IREN
-8.94%
$61.89
PLTR
-0.83%
$178.12
SOUN
-2.99%
$20.76
JBLU
-3.63%
$4.76
WTO
-88.87%
$0.13
CLSK
-13.92%
$19.97
SMR
-10.87%
$47.62
T
+0.46%
$26.19
RMBL
+60.50%
$3.21
GRAB
-3.54%
$5.71
AAPL
-0.75%
$247.45
ASST
-11.57%
$0.84
ADD
-25.47%
$0.05
SOND
+79.34%
$1.65
AUUD
+0.97%
$2.06
NOK
+0.53%
$5.68
WULF
-9.53%
$13.99
JOBY
-8.66%
$16.07
BAC
-4.03%
$50.17
MU
+4.60%
$200.77
IONQ
-9.33%
$65.65
APLD
-1.69%
$37.11
NEHC
+9.12%
$3.35
CLF
-0.07%
$13.95
SRM
+53.27%
$10.30
SATL
-29.71%
$2.91
BMNR
-4.90%
$51.16
TOVX
-47.86%
$0.43
KDLY
+1.29%
$0.79
SLNH
-1.39%
$4.23
AMC
-2.12%
$2.76
AMZN
-0.81%
$213.82
VHAI
-20.00%
$0.00
VIVK
-1.72%
$0.28
YYAI
-10.71%
$0.12
BURU
+1.07%
$0.34
EPWK
+26.46%
$0.09
IVF
+85.67%
$1.40
BITF
-18.39%
$5.28
RXRX
-7.21%
$6.29
CGBS
-39.47%
$0.03
COOT
+173.57%
$2.64
NVDA
+1.10%
$181.81
PLUG
-8.70%
$3.51
ADAP
+6.57%
$0.19
BYND
-22.39%
$0.52
YDKG
-54.14%
$0.08
NVTS
+3.10%
$15.63
RGTI
-14.85%
$47.97
DNN
-2.83%
$3.08
LAES
-2.09%
$7.49
NIO
-1.09%
$6.74
MIRA
+36.36%
$1.80
F
-0.12%
$11.74
SCNX
-17.63%
$0.58
BBD
+1.71%
$3.25
WHWK
+24.28%
$2.61
KVUE
-13.34%
$14.09
ACHR
-8.90%
$11.87
INTC
-0.83%
$36.84
TLRY
-8.33%
$1.54
HPE
-10.06%
$22.52
TSLA
-1.47%
$428.75
ONDS
-13.77%
$8.19
IONZ
+18.46%
$3.41
DFLI
-32.48%
$1.33
AXDX
-61.36%
$0.03
ETHD
+6.47%
$3.78
RIG
-2.56%
$3.22
CAN
-14.28%
$1.68
AAL
-4.88%
$11.89
AMD
-1.33%
$235.40
SOFI
-6.13%
$26.31
GDXD
-7.91%
$0.61
MARA
-11.62%
$20.18
BTBT
-9.11%
$3.69
GNPX
-43.39%
$0.47
QBTS
-9.62%
$40.47
BTG
+3.96%
$5.89
FEMY
+33.89%
$0.73
VSEE
-13.85%
$0.51
QS
-13.41%
$15.45
RR
-7.95%
$5.67
GPUS
-6.14%
$0.36
LGCB
+19.39%
$1.97
ABAT
-21.00%
$8.94
NAK
-4.34%
$2.64
SNAP
-1.83%
$7.76
CIFR
-10.98%
$18.72
WOK
+1.55%
$0.05
CRML
-14.52%
$19.42
QSI
-3.23%
$2.54
RF
-5.98%
$23.26
RGTZ
+30.51%
$11.35
PFE
-0.65%
$24.23
MASK
+17.35%
$0.57
UUUU
-12.80%
$21.79
QUBT
-12.12%
$18.65
KEY
-5.35%
$16.78
HBAN
-5.00%
$15.39
IREN
-8.94%
$61.89
PLTR
-0.83%
$178.12
SOUN
-2.99%
$20.76
JBLU
-3.63%
$4.76
WTO
-88.87%
$0.13
CLSK
-13.92%
$19.97
SMR
-10.87%
$47.62
T
+0.46%
$26.19
RMBL
+60.50%
$3.21
GRAB
-3.54%
$5.71
AAPL
-0.75%
$247.45
ASST
-11.57%
$0.84
ADD
-25.47%
$0.05
SOND
+79.34%
$1.65
AUUD
+0.97%
$2.06
NOK
+0.53%
$5.68
WULF
-9.53%
$13.99
JOBY
-8.66%
$16.07
BAC
-4.03%
$50.17
MU
+4.60%
$200.77
IONQ
-9.33%
$65.65
APLD
-1.69%
$37.11
NEHC
+9.12%
$3.35
CLF
-0.07%
$13.95
SRM
+53.27%
$10.30
SATL
-29.71%
$2.91
BMNR
-4.90%
$51.16
TOVX
-47.86%
$0.43
KDLY
+1.29%
$0.79
SLNH
-1.39%
$4.23
AMC
-2.12%
$2.76
AMZN
-0.81%
$213.82

Charts powered by TradingView


Market data may be delayed by 15 minutes or more and is provided by financial exchanges or third-party providers. AfterPullback does not verify or guarantee its accuracy and assumes no responsibility to do so. This website is not operated by a licensed attorney, accountant, or financial advisor. Nothing on this site constitutes financial advice or replaces consultation with a qualified professional who understands your specific circumstances. Always consult a licensed financial advisor before making investment decisions.